A host defense peptide mimetic, brilacidin, potentiates caspofungin antifungal activity against human pathogenic fungi
dos Reis, T. F.; de Castro, P. A.; Bastos, R.; Pinzan, C. F.; Souza, P. F.; Ackloo, S.; Hossain, M. A.; Drewry, D.; Alkhazraji, S.; Ibrahim, A.; Jo, H.; deGrado, W. F.; Goldman, G.
Show abstract
A. fumigatus is the main etiological agent of a group of heterogeneous diseases called aspergillosis of which the most lethal form is the invasive pulmonary aspergillosis (IPA). Fungicidal azoles and amphotericin B are the first line defense against A. fumigatus, but fungistatic echinocandins, such as caspofungin (CAS), can be used as salvage therapy for IPA. Here, we screened repurposing libraries and identified several compounds that potentiate CAS activity against A. fumigatus, including the host defense peptide mimetic, brilacidin (BRI). BRI converts CAS into a fungicidal drug and potentiates voriconazole (VOR) against A. fumigatus. BRI increases the ability of both CAS and VOR to control A. fumigatus biofilm growth. BRI depolarizes the A. fumigatus cell membrane leading to disruption of membrane potential. By using a combination of protein kinase inhibitors and screening of a catalytic subunit null mutant library, we identified the mitogen activated protein kinase (MAPK) MpkA and the phosphatase calcineurin as mediators of the synergistic action of BRI. These results suggest the most likely BRI mechanism of action for CAS potentiation is the inhibition of A. fumigatus cell wall integrity (CWI) pathway. BRI potentiates CAS activity against C. albicans, C. auris, and C. neoformans. Interestingly, BRI overcomes the CAS-acquired resistance in both A. fumigatus and C. albicans and the CAS-intrinsic resistance in C. neoformans. BRI also has an additive effect on the activity of posaconazole (POSA) against several Mucorales fungi. Cell toxicity assays and fungal burden studies in an immunosuppressed murine model of IPA showed that BRI combined with CAS is not toxic to the cells and significantly clears A. fumigatus lung infection, respectively. Our results indicate that combinations of BRI and antifungal drugs in clinical use are likely to improve the treatment outcome of IPA and other fungal infections.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Fenbendazole controls in vitro growth, virulence potential and animal infection in the Cryptococcusmodel 96%
- Identification of novel mutations contributing to azole tolerance of Aspergillus fumigatus through in vitro exposure to tebuconazole 95%
- Differential response of Candida species morphologies and isolates to fluconazole and boric acid 95%
Similar papers in this journal
- Revealing virulence potential of clinical and environmental Aspergillus fumigatus isolates using Whole-genome sequencing 94%
- Antimicrobial activity of cationic antimicrobial peptides against stationary phase bacteria 93%
- Copper Acts Synergistically with Fluconazole in Candida glabrata by Compromising Drug Efflux, Sterol Metabolism, and Zinc Homeostasis 93%
Similar papers in this journal
- Bisphosphonates synergistically enhance the antifungal activity of azoles in dermatophytes and other pathogenic molds 96%
- A Nanoemulsion as an Effective Treatment Against Human Pathogenic Fungi 95%
- Functional characterization of clinical isolates of the opportunistic fungal pathogen Aspergillus nidulans 95%
Similar papers in this journal
- Screening of chemical libraries for new antifungal drugs against Aspergillus fumigatus reveals the potential mechanism of action of miltefosine 97%
- Discovery of fungal-specific targets and inhibitors using chemical phenotyping of pathogenic spore germination 95%
- Antagonism of the azoles to olorofim and cross-resistance are governed by linked transcriptional networks in Aspergillus fumigatus 95%
Similar papers in this journal
- Genomic and phenotypic analysis of COVID-19-associated pulmonary aspergillosis isolates of Aspergillus fumigatus 94%
- Real-Time Flow Cytometry to assess qualitative and quantitative responses of oral pathobionts during exposure to antiseptics 93%
- A Novel Approach to Combat Pseudomonas aeruginosa: Repurposing Pharmaceuticals for Inhibition of Phospholipase A 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.